Loading
A phase 1/2 trial of ICP-B208 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07617493 by Beijing InnoCare Pharma Tech Co., Ltd., with 539 participants planned, started 2026-07-03 and due to reach its primary completion in 2030-12. Interventions recorded: ICP-B208.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares InnoCare Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/